Table 2.

Prospective clinical trials of first-line chemotherapy of esophageal cancer

Design	Treatment	n	Histology	RR	Median OS	Reference
Phase II	Cisplatin/5-FU	44	SCC	35%	8.25 months	41
Phase II	Paclitaxel/5-FU/cisplatin	60	SCC/AC	48%	10.8 months	49
Phase II	Cisplatin/irinotecan	35	SCC/AC	57%	14.6 months	50
Phase II	Cisplatin/vinorelbine	71	SCC	34%	6.8 months	51
Phase II	Oxaliplatin/5-FU	35	SCC/AC	40%	7.1 months	44
Phase II	Docetaxel/capecitabine	16	SCC/AC + GEJ	56%	15.8 months	54
Phase II	Docetaxel/cisplatin	76	GEJ + GASTRIC	26%	10.5 months	56
	Docetaxel/cisplatin/5-FU	79		43%	9.6 months
Phase II	Docetaxel/capecitabine	44	GEJ + GASTRIC	39%	9.4 months	53
Phase II	Oxaliplatin/capecitabine	43	AC + GEJ + GASTRIC	35%	6.4 months	46
Phase II (first, second I)	Oxaliplatin/capecitabine	51	SCC/AC + GEJ	39%	8 months	45
Phase II	Docetaxel/capecitabine/carboplatin	25	AC + GEJ + GASTRIC	48%	8 months	58
Phase II	Docetaxel/cisplatin/5-FU	60	GEJ + GASTRIC	47%	17.9 months	57
Phase III	ECF	249	SCC +	41%	9.9 months	55
	ECX	241	AC +	46%	9.9 months
	EOF	235	GEJ +	42%	9.3 months
	EOX	239	GASTRIC	48%	11.2 months
Phase II	Cisplatin/paclitaxel	35	SCC	49%	13 months	48
Phase II	Capecitabine/cisplatin	45	SCC	58%	11.2 months	43
Phase III	Cisplatin/S-1 Cisplatin/5-FU	82 88	GEJ + GASTRIC	29% 32%	8.6 months 7.9 months	42
Phase II	Docetaxel/cisplatin/5-FU	50	SCC/AC + GEJ + GASTRIC	47%	11.2 months	59
Phase II (first, second I)	Paclitaxel/capecitabine	32	SCC	75%	14.3 months	52
				45%	8.4 months
Phase II	Cisplatin/paclitaxel	46	SCC	57%	17 months	60

Notes: *P < 0.05; **P < 0.01.

Abbreviations: 5-FU, 5-fluorouracil; AC, adenocarcinoma; ECF, epirubicin/cisplatin/5-FU; ECX, epirubicin/capecitabine/5-FU; EOF, epirubicin/oxaliplatin/5-FU; EOX, epirubicin/oxaliplatin/capecitabine; GASTRIC, gastric cancer; GEJ, gastroesophageal junction carcinoma; S-1, oral fluoropyrimidine; SCC, squamous cell carcinoma; OS, overall survival; RR, response rate.